As part of the completion of the EAP proposal form, we will ask you to provide the details of the patient and confirm their eligibility. You will also need to obtain patient consent and authorization for participation and the use of their medical information for evaluation purposes. The form takes approximately 40 minutes to complete and can be started and saved at any point.
Your application will be reviewed by a local pharming representative who may contact you with further questions. If the application is approved, Pharming will then request further information to support the transfer of materials.
Submit an Expanded Access Proposal by visiting the EAP Application Portal. If you require any assistance in completing the form, please visit our Contact Page.
Patients who meet specific criteria may be eligible to participate in a clinical trial being held in their country. Please check clinical trial eligibility before applying to the Early Access Program.
For an overview of clinical trials currently being held or supported by Pharming, please visit Clinical Trials.
Leniolisib is approved for use in the US, and has been submitted to EMA for market authorization. If you are treating an APDS patient who is not in the US, you can request access to leniolisib through the expanded access program. Patients may be eligible if they fulfill the correct criteria outlined below: